Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats

Radiology

Volumn 247, Issue 2, 2008, Pages 391-399

  Raatschen, Hans Juergen ^a,b   Simon, Gerhard H ^a   Fu, Yanjun ^a   Sennino, Barbara ^a   Shames, David M ^a   Wendland, Michael F ^a   McDonald, Donald M ^a   Brasch, Robert C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; GADOLINIUM PENTETATE; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STUDENT T TEST; TUMOR GROWTH; ALGORITHM; ANALYSIS OF VARIANCE; ANIMAL; EXPERIMENTAL NEOPLASM; FEMALE; IMAGE PROCESSING; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSPECTIVE STUDY; RAT; REGRESSION ANALYSIS; VASCULARIZATION;

ALGORITHMS; ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; IMAGE PROCESSING, COMPUTER-ASSISTED; LEAST-SQUARES ANALYSIS; MAGNETIC RESONANCE IMAGING; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROSPECTIVE STUDIES; RATS; TUMOR MARKERS, BIOLOGICAL;

EID: 44449160916     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2472070363     Document Type: Article

References (49)

1. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
2. Couvelard A, Paraf F, Gratio V, et al. Angiogenesis in the neoplastic sequence of Barrett's oesophagus: correlation with VEGF expression. J Pathol 2000;192:14-18.
3. Dobbs SP, Brown LJ, Ireland D, et al. Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Ann Diagn Pathol 2000;4:286-292.
4. Dobbs SP, Hewett PW, Johnson IR, Carmichael J, Murray JC. Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. Br J Cancer 1997;76:1410-1415.
5. Magennis DP. Angiogenesis: a new prognostic marker for breast cancer. Br J Biomed Sci 1998;55:214-220.
6. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 1996;:167-190.
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
8. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38:1564-1579.
9. Jain RK. Transvascular and interstitial transport in tumors. Adv Exp Med Biol 1988;242:215-220.
10. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29:3-9.
11. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992;3:89-96.
12. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
13. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9:713-725.
14. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-1380.
15. Schwickert HC, Stiskal M, Roberts TP, et al. Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. Radiology 1996;198:893-898.
16. Preda A, Novikov V, Moglich M, et al. Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation. Eur Radiol 2005;15:2268-2275.
17. Brasch R, Pham C, Shames D, et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997;7:68-74.
18. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/ vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999;237:97-132.
19. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
20. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987;6:559-593.
21. Jain RK, Gerlowski LE. Extravascular transport in normal and tumor tissues. Crit Rev Oncol Hematol 1986;5:115-170.
22. Gossmann A, Okuhata Y, Shames DM, et al. Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR imaging in the rat: comparison of macromolecu-lar and small-molecular contrast media - preliminary experience. Radiology 1999;213:265-272.
23. Brasch RC, Shames DM, Cohen FM, et al. Quantification of capillary permeability to macromolecular magnetic resonance imaging contrast media in experimental mammary adenocarcinomas. Invest Radiol 1994;29(suppl 2):S8-S11.
24. Gossmann A, Helbich TH, Mesiano S, et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 2000;183:956-963.
25. Turetschek K, Roberts TP, Floyd E, et al. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J Magn Reson Imaging 2001;13:882-888.
26. Daldrup-Link HE, Rydland J, Helbich TH, et al. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. Radiology 2003;229:885-892.
27. Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998;171:941-949.
28. Turetschek K, Preda A, Floyd E, et al. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model. Eur J Nucl Med Mol Imaging 2003;30:448-455.
29. Preda A, Novikov V, Moglich M, et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 2004;20:865-873.
30. Turetschek K, Preda A, Floyd E, et al. MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model. Acad Radiol 2002;9(suppl 2):S519-S520.
31. Wiart M, Fournier LS, Novikov VY, et al. Magnetic resonance imaging detects early changes in microvascular permeability in xenograft tumors after treatment with the matrix metalloprotease inhibitor Prinomastat. Technol Cancer Res Treat 2004;3:377-382.
32. Pham CD, Roberts TP, van Bruggen N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998;16:225-230.
33. Cailleau R, Olive M, Cruciger QV. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 1978;14:911-915.
34. Ogan MD, Schmiedl U, Moseley ME, Grodd W, Paajanen H, Brasch RC. Albumin labeled with Gd-DTPA: an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging - preparation and characterization. Invest Radiol 1987;22:665-671.
35. Olszewski AJ, Grossbard ML, Kozuch PS. The horizon of antiangiogenic therapy for colorectal cancer. Oncology (Williston Park) 2005;19:297-306.
36. Midgley R, Kerr D. Bevacizumab: current status and future directions. Ann Oncol 2005;16:999-1004.
37. Shames DM, Kuwatsuru R, Vexler V, Muhler A, Brasch RC. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med 1993;29:616-622.
38. Preda A, Turetschek K, Daldrup H, et al. The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors. Invest Radiol 2005;40:349-354.
39. Roberts TP, Brasch RC, Schwickert HC, et al. Quantification of tissue gadolinium concentration using magnetic resonance imaging: comparison of ultrashort inversion time inversion recovery echoplanar and dynamic three-dimensional spoiled gradient-recalled approaches with in vitro measurements. Acad Radiol 1996;3(suppl 2):S282-S285.
40. Daldrup HE, Shames DM, Husseini W, Wendland MF, Okuhata Y, Brasch RC. Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. Magn Reson Med 1998;40:537-543.
41. Foster DM, Boston RC, Jacquez JA, Zech L. A resource facility for kinetic analysis: modeling using the SAAM computer programs. Health Phys 1989;57(suppl 1):457-466.
42. Zar JH. Biostatistical analysis. 4th ed. Englewood Cliffs, NJ: Prentice-Hall, 1999.
43. Koukourakis MI, Giatromanolaki A, Sivridis E, Fezoulidis I. Cancer vascularization: implications in radiotherapy? Int J Radiat Oncol Biol Phys 2000;48:545-553.
44. Matsubayashi R, Matsuo Y, Edakuni G, Satoh T, Tokunaga O, Kudo S. Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 2000;217:841-848.
45. Turetschek K, Huber S, Helbich T, et al. Dynamic MRI enhanced with albumin-(Gd-DTPA)30 or ultrasmall superparamagnetic iron oxide particles (NC100150 injection) for the measurement of microvessel permeability in experimental breast tumors. Acad Radiol 2002;9(suppl 1):S112-S114.
46. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986;31:288-305.
47. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133:95-109.
48. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-3964.
49. Roberts TP, Helbich TH, Ley S, et al. Utility (or not) of Gd-DTPA-based dynamic MRI for breast cancer diagnosis and grading. Acad Radiol 2002;9(suppl 1):S261-S265.